C4X Discovery Company

C4X Discovery is a company that develops a drug discovery engine to deliver best-in-class small-molecule medicines efficiently. The preclinical discovery portfolio is focused on inflammation, neurodegeneration, and oncology. The company has unique software platforms, Taxonomy3 and Conformetrix, that enable the rapid design and discovery of novel and potent drugs. Taxonomy3 is used to analyse complex genetic datasets to identify and characterise novel drug target candidates. Conformetrix technology allows the dynamic 3D shapes of free drug molecules to be precisely measured from experimental data, giving medicinal chemists new and unprecedented insights into drug molecules' behaviour and physical properties. C4X Discovery's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue-generating preclinical licensing deals.
Industry: AI for Longevity
Headquarters: Manchester, United Kingdom
Founded Date: 2007
Employees Number: 11-50
Funding Status: IPO
Investors Number: 2
Total Funding: £5 000 000
Estimated Revenue: £780 000 - £7 800 000
Last Funding Date: 09-06-2016
Last Funding Type: Post-IPO Equity

Visit Website
contact@c4xdiscovery.com
Register and Claim Ownership